—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Rhythm Pharmaceuticals Inc (RYTM) — Technical state

As of 2026-11-10 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 43 out of 100 (momentum 68 · quality 21 · valuation 7), as of 2026-11-11.
  • Signal: Recovery attempt under the 200-day — Trades +18.2% vs the 50-day and +17.3% vs the 200-day average, 6.8% below the 52-week high and +53% off the 52-week low; a death cross printed 7 sessions ago. Computed from daily closes. (as of 2026-11-10)
  • Trend: Rhythm Pharmaceuticals Inc trades 18.2% above its 50-day and 17.3% above its 200-day moving average. (as of 2026-11-10)

Rhythm Pharmaceuticals develops treatments for rare genetic forms of obesity linked to faults in the melanocortin-4 receptor pathway that controls hunger. Its approved drug, setmelanotide, treats several of these inherited conditions, and it is testing further MC4R-pathway compounds, including an oral pill and a longer-acting injectable, in patients with related genetic and hypothalamic obesities.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the RYTM overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Recovery attempt under the 200-day

Trades +18.2% vs the 50-day and +17.3% vs the 200-day average, 6.8% below the 52-week high and +53% off the 52-week low; a death cross printed 7 sessions ago. Computed from daily closes.

The moving-average stack

Continue: the RYTM chart & overview · quality & forensics · the earnings record · the signal board

FAQ · from the current data · as of 2026-11-10

Quick answers

What is the current Closelooknet signal on RYTM?

Recovery attempt under the 200-day — Trades +18.2% vs the 50-day and +17.3% vs the 200-day average, 6.8% below the 52-week high and +53% off the 52-week low; a death cross printed 7 sessions ago. Computed from daily closes. As of 2026-11-10; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is RYTM above its 50-day and 200-day moving averages?

As of 2026-11-10, Rhythm Pharmaceuticals Inc trades +18.2% above its 50-day and +17.3% above its 200-day average, with the 20-day +19.8% away.

How far is RYTM from its 52-week high?

6.8% below the 52-week high and 53% above the 52-week low, as of 2026-11-10.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.